- Raw materials
- Antimetabolites
- Chromic citrate
Chromic citrate API Manufacturers & Suppliers
0 verified results
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Commercial-scale Suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Chromic citrate is listed?
Join our notification list by following this page.
Join our notification list by following this page.
List your company
Are you a supplier of Chromic citrate or other APIs and are you looking to list your company on Pharmaoffer?
Click the button below to find out more
Click the button below to find out more
Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?
Click the button below to switch over to the contract services area of Pharmaoffer.
Click the button below to switch over to the contract services area of Pharmaoffer.
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency
|
Supplier trade data access
|
Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Chromic citrate | CAS No: 57072-40-9 | GMP-certified suppliers
A medication that supports total parenteral nutrition by maintaining chromium levels to prevent deficiency and support glucose metabolism in patients requiring intravenous supplementation.
Therapeutic categories
Drugs that are Mainly Renally Excreted
Generic name
Chromic citrate
Molecule type
small molecule
CAS number
57072-40-9
DrugBank ID
DB14526
Approval status
Experimental drug
Primary indications
- Indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN), to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms
Product Snapshot
- Chromic citrate is an injectable inorganic salt formulation intended for parenteral administration
- Its primary use is as a micronutrient supplement in total parenteral nutrition to maintain chromium serum levels and prevent deficiency
- The compound is currently classified as experimental and does not have FDA or EMA approval for general clinical use
Clinical Overview
Chromic citrate (CAS Number 57072-40-9) is an organic compound belonging to the class of tricarboxylic acids and derivatives. It is primarily used as a supplement in intravenous solutions for total parenteral nutrition (TPN). The purpose of chromic citrate administration in this context is to maintain adequate chromium serum levels and prevent depletion of endogenous chromium stores, which can otherwise lead to deficiency-related clinical manifestations.
Chromium, in its trivalent form, plays a critical role in glucose metabolism as part of the glucose tolerance factor, which is essential for insulin activity. It enhances insulin-mediated biological processes by increasing insulin binding to target cells, upregulating insulin receptor density, and activating insulin receptor kinase, thereby improving insulin sensitivity. In patients with chromium deficiency, intravenous chromium administration has been shown to normalize abnormal glucose tolerance curves, indicating restoration of glucose homeostasis.
The mechanism of action involves potentiation of the insulin signaling cascade. Chromic citrate influences downstream effector molecules in the insulin receptor pathway, promoting phosphorylation events that activate phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt). This signaling cascade facilitates translocation of glucose transporter-4 (GLUT-4) vesicles to the cell membrane, enhancing cellular glucose uptake. Additionally, chromium modulates membrane cholesterol content to increase fluidity, thereby stimulating GLUT-4 translocation through an insulin receptor-independent route. It also inhibits protein tyrosine phosphatase-1B (PTP-1B), a negative regulator of insulin signaling, reduces endoplasmic reticulum stress implicated in insulin resistance, and transiently activates AMP-activated protein kinase (AMPK), further supporting glucose uptake.
Chromic citrate is primarily eliminated through renal excretion. It remains an experimental drug, with no broad regulatory approvals for clinical use beyond nutritional supplementation in TPN formulations. Safety profiles should consider potential toxicity related to chromium accumulation, especially in patients with impaired renal function, as excessive chromium exposure may induce oxidative stress and cytotoxic effects.
For sourcing and quality assurance, procurement of chromic citrate API requires stringent control of purity, residual solvents, and heavy metal contamination, given chromium’s narrow therapeutic window and potential toxicity. Compliance with pharmacopeial standards and traceability of raw materials is essential to ensure suitability for intravenous nutritional applications.
Chromium, in its trivalent form, plays a critical role in glucose metabolism as part of the glucose tolerance factor, which is essential for insulin activity. It enhances insulin-mediated biological processes by increasing insulin binding to target cells, upregulating insulin receptor density, and activating insulin receptor kinase, thereby improving insulin sensitivity. In patients with chromium deficiency, intravenous chromium administration has been shown to normalize abnormal glucose tolerance curves, indicating restoration of glucose homeostasis.
The mechanism of action involves potentiation of the insulin signaling cascade. Chromic citrate influences downstream effector molecules in the insulin receptor pathway, promoting phosphorylation events that activate phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt). This signaling cascade facilitates translocation of glucose transporter-4 (GLUT-4) vesicles to the cell membrane, enhancing cellular glucose uptake. Additionally, chromium modulates membrane cholesterol content to increase fluidity, thereby stimulating GLUT-4 translocation through an insulin receptor-independent route. It also inhibits protein tyrosine phosphatase-1B (PTP-1B), a negative regulator of insulin signaling, reduces endoplasmic reticulum stress implicated in insulin resistance, and transiently activates AMP-activated protein kinase (AMPK), further supporting glucose uptake.
Chromic citrate is primarily eliminated through renal excretion. It remains an experimental drug, with no broad regulatory approvals for clinical use beyond nutritional supplementation in TPN formulations. Safety profiles should consider potential toxicity related to chromium accumulation, especially in patients with impaired renal function, as excessive chromium exposure may induce oxidative stress and cytotoxic effects.
For sourcing and quality assurance, procurement of chromic citrate API requires stringent control of purity, residual solvents, and heavy metal contamination, given chromium’s narrow therapeutic window and potential toxicity. Compliance with pharmacopeial standards and traceability of raw materials is essential to ensure suitability for intravenous nutritional applications.
Identification & chemistry
| Generic name | Chromic citrate |
|---|---|
| Molecule type | Small molecule |
| CAS | 57072-40-9 |
| UNII | LQC76G8WUE |
| DrugBank ID | DB14526 |
Pharmacology
| Summary | Chromium is an essential micronutrient that potentiates insulin signaling by enhancing the kinase activity of the insulin receptor β-subunit and activating downstream effectors such as PI3-kinase and Akt, promoting GLUT-4 translocation and glucose uptake. It also modulates membrane cholesterol to facilitate insulin-independent GLUT-4 translocation and attenuates negative regulators of insulin signaling including PTP-1B and ER stress pathways. Chromium supports normal glucose metabolism and insulin sensitivity, particularly relevant in maintaining metabolic homeostasis during total parenteral nutrition. |
|---|---|
| Mechanism of action | Chromium is an essential nutrient involved in the metabolism of glucose, insulin and blood lipids. Its role in potentiating insulin signalling cascades has been implicated in several studies. Chromium upregulates insulin-stimulated insulin signal transduction via affecting effector molecules downstream of the insulin receptor (IR). IR-mediated signalling pathway involves phoshorylation of multiple intracellular domains and protein kinases, and downstream effector molecules . Upon activation by ligands, intracellular β-subunit of IR autophosphorylates and activates tyrosine kinase domain of the IR, followed by activation and phosphorylation of regulatory proteins and downstream signalling effectors including phosphatidylinositol 2-kinase (PI3K). PI3K activates further downstream reaction cascades to activate protein kinase B (Akt) to ultimately promote translocation of glucose transporter-4 (Glut4)-vesicles from the cytoplasm to the cell surface and regulate glucose uptake . Chromium enhances the kinase activity of insulin receptor β and increases the activity of downstream effectors, pI3-kinase and Akt. Under insulin-resistant conditions, chromium also promotes GLUT-4 transporter translocation that is independent of activity of IR, IRS-1, PI3-kinase, or Akt; chromium mediates cholesterol efflux from the membranes via increasing fluidity of the membrane by decreasing the membrane cholesterol and upregulation of sterol regulatory element-binding protein . As a result, intracellular GLUT-4 transporters are stimulated to translocate from intracellular to the plasma membrane, leading to enhanced glucose uptake in muscle cells . Chromium attenuates the activity of PTP-1B _in vitro,_ which is a negative regulator of insulin signaling. It also alleviates ER stress that is observed to be elevated the suppression of insulin signaling. ER stress is thought to activate c-Jun N-terminal kinase (JNK), which subsequently induces serine phosphorylation of IRS and aberration of insulin signalling . Transient upregulation of AMPK by chromium also leads to increased glucose uptake . |
| Pharmacodynamics | Trivalent chromium is part of glucose tolerance factor, an essential activator of insulin-mediated reactions. Chromium helps to maintain normal glucose metabolism and peripheral nerve function. Chromium increases insulin binding to cells, increases insulin receptor density and activates insulin receptor kinase leading to enhanced insulin sensitivity . In chromium deficiency, intravenous administration of chromium resulted in normalization of the glucose tolerance curve from the diabetic-like curve typical of chromium deficiency. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Cytochrome b5 | Humans |
ADME / PK
| Absorption | Chromium compounds are both absorbed by the lung and the gastrointestinal tract. Oral absorption of chromium compounds in humans can range between 0.5% and 10%, with the hexavalent (VI) chromium more easily absorbed than the trivalent (III) form . Absorption of chromium from the intestinal tract is low, ranging from less than 0.4% to 2.5% of the amount consumed . Vitamin C and the vitamin B niacin is reported to enhance chromium absorption . Most hexavalent Cr (VI) undergoes partial intragastric reduction to Cr (III) upon absorption, which is an action mainly mediated by sulfhydryl groups of amino acids . Cr (VI) readily penetrates cell membranes and chromium can be found in both erythrocytes and plasma after gastrointestinal absorption of Cr (IV). In comparison, the presence of chromium is limited to the plasma as Cr (III) displays poor cell membrane penetration . Once transported through the cell membrane, Cr (VI) is rapidly reduced to Cr (III), which subsequently binds to macromolecules or conjugate with proteins. Cr (III) may be bound to transferrin or other plasma proteins, or as complexes, such as glucose tolerance factor (GTF). |
|---|---|
| Half-life | The elimination half-life of hexavalent chromium is 15 to 41 hours . |
| Protein binding | In the blood, 95% of chromium (III) is bound to large molecular mass proteins, such as transferrin, while a small proportion associates with low molecular mass oligopeptides . Serum chromium is bound to transferrin in the beta globulin fraction. |
| Metabolism | The metabolism of Cr (VI) involves reduction by small molecules and enzyme systems to generate Cr (III) and reactive intermediates. During this process, free radicals can be generated, which is thought to induce damage of cellular components and cause toxicity of chromium . The metabolites bind to cellular constituents . |
| Route of elimination | Absorbed chromium is excreted mainly in the urine, accounting for 80% of total excretion of chromium; small amounts are lost in hair, perspiration and bile . Chromium is excreted primarily in the urine by glomerular filtration or bound to a low molecular-weight organic transporter . |
| Volume of distribution | Absorbed chromium is distributed to all tissues of the body and its distribution in the body depends on the species, age, and chemical form . Circulating Cr (III) following oral or parenteral administration of different compounds can be taken up by tissues and accumulates in the liver, kidney, spleen, soft tissue, and bone . |
| Clearance | Excretion of chromium is via the kidneys ranges from 3 to 50 μg/day. The 24-hour urinary excretion rates for normal human subjects are reported to be 0.22 μg/day . |
Formulation & handling
- Chromic citrate is a small molecule suitable for oral formulations due to its moderate water solubility.
- Its low LogP value indicates hydrophilic characteristics, potentially affecting membrane permeability and absorption.
- Stability considerations should focus on its acidic nature and potential interactions with alkaline excipients during formulation.
Regulatory status
Safety
| Toxicity | Oral LD50 for Cr (VI) is 135 - 175 mg/kg in mouse and 46 - 113 mg/kg in rat . Oral LD50 for Cr (III) in rat is >2000 mg/kg . LD50 of chromium (III) oxide in rats is reported to be > 5g/kg . Other LD50 values reported for rats include: 3.5 g/kg (CI 3.19-3.79 g/kg) for chromium sulphate; 11.3 g/kg for chromium (III) acetate; 3.3 g/kg for chromium nitrate; and 1.5 g/kg for chromium nitrate nonahydrate . Acute overdose of chromium is rare and seriously detrimental effects of hexavalent chromium are primarily the result of chronic low-level exposure . In case of overdose with minimal toxicity following acute ingestion, treatment should be symptomatic and supportive . There is no known antidote for chromium toxicity. Hexavalent chromium is a Class A carcinogen by the inhalation route of exposure and Class D by the oral route . The oral lethal dose in humans has been estimated to be 1-3 g of Cr (VI); oral toxicity most likely involves gastrointestinal bleeding rather than systemic toxicity . Chronic exposure may cause damage to the following organs: kidneys, lungs, liver, upper respiratory tract [MSDS]. Soluble chromium VI compounds are human carcinogens. Hexavalent chromium compounds were mutagenic in bacteria assays and caused chromosome aberrations in mammalian cells. There have been associations of increased frequencies of chromosome aberrations in lymphocytes from chromate production workers . In human cells _in vitro_, Cr (VI) caused chromosomal aberrations, sister chromatid exchanges and oxidative DNA damage . |
|---|
High Level Warnings:
- Hexavalent chromium compounds are classified as human carcinogens via inhalation and exhibit mutagenic potential in vitro and in vivo assays
- Acute oral toxicity of Cr(VI) is significantly higher than Cr(III), with LD50 values for Cr(VI) in rodents ranging from 46 to 175 mg/kg, whereas Cr(III) compounds have substantially higher LD50 values (›1
- 5 g/kg)
Chromic citrate is a type of Antimetabolites
Antimetabolites are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various diseases, particularly cancer. These compounds are structurally similar to naturally occurring metabolites essential for cellular processes such as DNA and RNA synthesis. By mimicking these metabolites, antimetabolites interfere with the normal functioning of cellular pathways, leading to inhibition of cancer cell growth and proliferation.
One of the widely used antimetabolites is methotrexate, a folic acid antagonist that inhibits the enzyme dihydrofolate reductase, disrupting the production of DNA and RNA. This disruption impedes the growth of rapidly dividing cancer cells. Another common antimetabolite is 5-fluorouracil (5-FU), which inhibits the enzyme thymidylate synthase, thereby interfering with DNA synthesis and inhibiting cancer cell proliferation.
Antimetabolites can be classified into several subcategories based on their mechanism of action and chemical structure. These include purine and pyrimidine analogs, folic acid antagonists, and pyrimidine synthesis inhibitors. Examples of antimetabolites in these subcategories include azathioprine, cytarabine, and gemcitabine.
Despite their effectiveness, antimetabolites can exhibit certain side effects due to their interference with normal cellular processes. These side effects may include gastrointestinal disturbances, myelosuppression (reduced production of blood cells), and hepatotoxicity.
In conclusion, antimetabolites are a vital category of pharmaceutical APIs used in the treatment of various diseases, especially cancer. By mimicking natural metabolites and disrupting crucial cellular processes, these compounds effectively inhibit cancer cell growth and proliferation. However, their usage should be carefully monitored due to potential side effects.
